| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney fun...
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular ...
HC Wainwright & Co. analyst Yi Chen reiterates Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and maintains $9 price ta...
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.24)...